Raquel Jiménez
University of Barcelona
10 Papers
54 Citations
Raquel Jiménez is an academic researcher from University of Barcelona. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 5, co-authored 10 publications.
Chat about Author
Papers
Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach
Joan Bladé,Carlos Fernández de Larrea,Laura Rosiñol,María Teresa Cibeira,Raquel Jiménez,Ray L. Powles +5 more
TL;DR: The incidence of EMPs in patients with MM is high and is associated with poor outcome in patients treated conventionally, and a potential first-line treatment option seems to be a bortezomib-containing regimen followed by ASCT, whenever possible.
351
A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)
Mark A. Dawson,Eytan M. Stein,Brian J. P. Huntly,Anastasios Karadimitris,Manali Kamdar,Carlos Fernández de Larrea,Michael Dickinson,Paul Yeh,Naval Daver,Aristeidis Chaidos,Martin S. Tallman,Raquel Jiménez,Thierry Horner,January Baron,John Brennan,Geraldine Ferron-Brady,Yuehui Wu,Natalie Karpinich,Brandon E. Kremer,Arindam Dhar,Gautam Borthakur +20 more
TL;DR: In this article, the authors evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK525762 in relapsed and refractory acute myeloid leukemia (AML) patients.
37
Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma.
C. Fernández de Larrea,Raquel Jiménez,Laura Rosiñol,Eva Giné,Natalia Tovar,MT Cibeira,Francesc Fernández-Avilés,Cristina Martínez,M Rovira,J. Bladé +9 more
TL;DR: This study analyzed the type of relapse or progression, clinical features including the presence of extramedullary involvement and time to next treatment in 211 patients who underwent melphalan-based autologous SCT over an 18-year period at an institution.
33
Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution.
Laura Rosiñol,Raquel Jiménez,M Rovira,C Martínez,Francesc Fernández-Avilés,Pedro Marín,María Suárez-Lledó,Gonzalo Gutiérrez-García,C. Fernández de Larrea,Enric Carreras,Alvaro Urbano-Ispizua,J. Bladé +11 more
TL;DR: A proportion of patients with high-risk myeloma (early relapse and newly diagnosed ultrahigh risk) may obtain long-term disease control with allo-HCT and new approaches aimed at decreasing the incidence of aGVHD, and consequently to decrease the TRM are needed.
10
Incidence and Outcome of Soft-Tissue Plasmacytomas in Patients with Multiple Myeloma before and after the Introduction of Novel Drugs
Raquel Jiménez,Laura Rosiñol,María Teresa Cibeira,Carlos Fernández de Larrea,Esther Bladé,Natalia Tovar,Joan Bladé +6 more
TL;DR: Patients with PPs at diagnosis had similar survival than those without Ps while patients with EMPs had poorer outcome than those with P Ps or patients with no soft-tissue involvement, both at diagnosis and at relapse.
6